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Polyglutamine Expansions: Minireview
Proteolysis, Chaperones,
and the Dangers of Promiscuity
method has been compromised by the polyQ expansion.
The role of ubiquitination in one polyQ expansion dis-
ease, spinocerebellar ataxia type 1 (SCA1), has recently
been explored (Cummings et al., 1999). In HeLa cells,
active proteasomes appear to decrease the amount of
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polyubiquitinated SCA1/ataxin-1 protein aggregation,Harvard Medical School
suggesting that proteolytic degradation represents oneBoston, Massachusetts 02115
way for the cell to remove polyQ protein. In vitro, ubiquiti-
nated polyQ-expanded ataxin-1 protein was more resis-
tant to proteasome-mediated degradation than the wild-At least eight diseases share a common mechanism of
type polyQ protein. These data suggest that the mutantonset: the expansion of a CAG repeat in the genome,
form of a polyQ protein is indeed more resistant to deg-leading to the production of mutant protein with an ex-
radation than the wild-type form. Intriguingly, mice car-panded polyglutamine (polyQ) repeat. Typically, the dis-
rying a deletion in the best-characterized ubiquitin li-ease form of each protein has a polyQ tract of greater
gase, UBE3, show increased susceptibility to mutantthan 35 glutamine residues, whereas the wild-type pro-
SCA1 yet have decreased levels of intranuclear inclu-tein may contain around 20 glutamines. Because of
sions. This suggests that nuclear inclusions are not inthese similarities, unifying themes with regard to mecha-
themselves toxic to cells. Although no evidence wasnism have begun to emerge from studies of these dis-
presented to show that SCA1 protein was less ubiquiti-eases. Investigations have focused on three altered
nated in the ube3 mutant mice, these data strongly sug-characteristics of the mutant protein: subcellular local-
gest that ubiquitination may represent an attempt byization, proteolytic processing, and the formation of in-
cells to protect themselves from polyQ-mediated tox-tranuclear inclusions. In six of these diseases, the mu-
icity.tant protein accumulates in the nucleus of a neuronal
Similarly, in studies of huntingtin (htt) -mediated toxic-cell population specific to each disease. In each case,
ity in primary cultures of striatal neurons, Saudou et al.the mutant protein forms aggregates termed neuronal
(1998) found that cotransfection of a dominant-negativeinclusions (NIs) that also contain ubiquitin (Ub). Neurons
Cdc34 ubiquitin-conjugating enzyme decreased nuclearcontaining these aggregates eventually undergo apo-
aggregate formation by htt, but without decreasing cellptosis, with corresponding decreases in brain mass in
toxicity. Finally, by mutating an endogenous NLS inaffected individuals. These observations have led to
ataxin-1 (Klement et al., 1998) or by adding a nuclearmodels predicting that altered proteolytic processing of
export sequence (NES) to htt (e.g., Saudou et al., 1998),the mutant proteins would cause their relocalization
two groups have shown that polyQ toxicity requires nu-from the cytoplasm to the nucleus, where their aggrega-
clear localization. Together, the studies by Cummingstion leads to toxicity. We will discuss recent studies of
et al., Klement et al., and Saudou et al. strongly suggestthe cell biology of polyQ diseases with particular regard
that the toxicity that eventually leads to death in polyQto the roles of both ubiquitination and nuclear transport.
repeat diseases is likely to occur via soluble polyQ-These studies suggest that nuclear aggregation is not
expanded protein in the nucleus. Ubiquitination of thea causative agent in cell toxicity and identify new candi-
protein may not be required for toxicity. If they are rele-
dates for the role of toxic partner to the polyQ expansion.
vant at all, the nuclear inclusions are likely to be protec-
Traditionally, a major role of protein ubiquitination has
tive, not toxic. One protective role for ubiquitination
been thought to be the directing of the target protein could be to drive the formation of nuclear inclusions
to the proteasome for degradation. Thus, the detection that sequester the toxic polyQ-expanded protein.
of ubiquitinated forms of mutant disease proteins sug- Because of the clinical correlation between aggregate
gested that the polyQ expansion could lead to an unusu- formation in specific neurons and the degeneration of
ally stable conformation of the protein that is resistant these neurons in affected individuals, it has been widely
to proteolysis. Because diseases caused by polyQ tract held that polyQ-containing NIs themselves are toxic
expansion typically take several years to manifest them- (e.g., Davies et al., 1997). This has led to considerable
selves, one model had been that the wild-type form of confusion in the literature: when assessing ªnuclear lo-
the protein could be turned over, whether by ubiquitin- calization,º some workers count only nuclear aggre-
mediated proteolysis or by some other pathway. Abnor- gates, while others also consider diffuse nuclear staining
mal stabilization of the mutant form, in contrast, would to be relevant. Similarly, much effort has been devoted
lead to the slow buildup of some toxic entity and even- to understanding how aggregates form, while evidence
tual cell death. In this scenario, the ubiquitinated mutant such as that presented by Cummings et al. (1999) sug-
protein could represent a blocked intermediate in the gests that they may not be important in understanding
turnover pathway used by the wild-type protein. Alterna- the mechanisms of cellular toxicity. Nuclear localization
tively, ubiquitination could represent an attempt by the is clearly required for toxicity, so how does the toxic
cell to degrade a protein whose turnover by the usual protein enter the nucleus? In the case of Huntington's
Disease (HD), the htt protein is much too large to enter
the nucleus unless it is being imported by a signal-* To whom correspondence should be addressed (e-mail: pamela_
silver@dfci.harvard.edu). mediated process. Visual inspection of the amino acid
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that does not require their aggregation into nuclear in-Table 1. Potential Nuclear Localization Sequences in the htt
Protein clusions. What then is the mechanism of toxicity? Be-
cause aggregates appear to represent an attempt by91±101 KKELSATKKDR (bipartite)
the cells to protect themselves from toxicity, we may416±444 RSRSGSIVELIAGGGSSCSPVLSRKQKGK (bipartite)
assume that many proteins that have been shown to439±444 RKQKGK
1184±1188 RRKGK localize in nuclear inclusions represent a cellular attempt
to mitigate toxicity (but see below). These proteins in-The polyQ region starts at residue 18, and the residue numbering
clude the 20S proteasome, the HSP40 and HSP70 chap-used here assumes a wild-type glutamine repeat length of 23 resi-
dues. The first three of these NLSs lie within a predicted 56 kDa erones, as well as ubiquitin. Other proteins, such as
N-terminal fragment that could be produced by caspase cleavage. the TATA-binding protein (TBP), could be recruited into
aggregates because they are present in the nucleus in
large amounts. It is worth noting that TBP itself contains
a polyQ repeat that could mediate its association with
sequence of htt reveals four potential nuclear localiza- polyQ expansions in the manner proposed by Perutz et
tion sequences, three of which lie in a predicted 56 al. (1994). Could the recruitment of functionally impor-
kDa caspase-mediated proteolytic fragment (Table 1). tant proteins such as TBP into aggregates be a reflection
Relocalization of full-length endogenous or transfected of an inappropriate, noxious association with a polyQ
htt protein from the cytoplasm to nuclei has been ob- expansion? If this is the case, identifying those proteins
served in some systems (e.g., Hoogeveen et al., 1993; that seed aggregates could yield insights into the mech-
Lunkes and Mandel, 1998). Furthermore, mutant, polyQ- anism of toxicity. Promiscuity, the indiscriminate mixing
expanded fragments of either ataxin-3 or the unrelated of nuclear components, could hold the key to polyQ-
ataxin-1 can recruit full-length, polyQ-expanded ataxin-3 mediated toxicityÐand chaperones could well repre-
from the cytoplasm into nuclear aggregates (Perez et sent an attempt to keep these unsuitable partners apart.
al., 1998). Because of the relatively large size of these Insights into this possibility may arise from recent
proteins, passive entry into the nucleus by diffusion studies of chaperones and transcription factors in polyQ
seems unlikely, suggesting that active import by nuclear expansion disease. In two genetic systemsÐbudding
transport factors is occurring. yeast (Krobitsch and Lindquist, 2000) and Drosophila
How could a putative toxic fragment be produced? (Kazemi-Esfarjani and Benzer, 2000)Ðchaperones have
Expression of polyQ stretches can cause caspase acti- been shown to modulate aggregate formation and/or
vation (Ona et al., 1999; Sanchez et al., 1999). Triggering toxicity. In yeast, the increased expression of any one
a caspase cascade could lead to the activation of a of three chaperonesÐthe Hsp40/Hdj1 homolog, Sis1; an
protease that would act on a polyQ-containing protein Hsp70 homolog, Ssa1; or Hsp104Ðappeared to disrupt
to lead to the production of the toxic fragment. A priori, polyQ aggregates. In sharp contrast, deletion of Hsp104
this fragment could be either the polyQ-containing do- had the unexpected effect of preventing aggregate for-
main or some other part of the protein. The best evi- mation, suggesting that the activity of at least this chap-
dence that the polyQ domain itself is toxic comes from erone may be required for aggregate formation. If aggre-
experiments where expression of a small portion of a gates are seeded by the toxic interaction between a
disease protein, with a polyQ expansion in the disease disease protein and a cellular target, then the identifica-
range, is sufficient to cause disease (e.g., Mangiarini et tion of ways to modulate aggregate formation will have
al., 1996). Such observations have led to the assumption implications for drug discovery. In Drosophila, a homo-
that the polyQ-containing fragment is the cause of cellu- log of Hdj1 and another J-domain protein (dTPR2) were
lar toxicity, but this is not necessarily the case. All such identified as suppressors of polyQ-mediated toxicity
experiments have been performed in backgrounds con- (Kazemi-Esfarjani and Benzer, 2000). Importantly, these
taining endogenous polyQ protein where the repeat is in two suppressors decreased toxicity but did not de-
the wild-type range. If the expressed, polyQ-expanded crease the frequency of aggregate formation. This sug-
protein is driving the clipping of endogenous protein, gests that chaperones may interfere with the interaction
the putative toxic nonpolyQ fragment could still be pro- between the toxic form of the disease protein and its
duced. This could explain why toxicity would take so target. Finally, in three different mammalian cell types,
long to appear, even in models where the polyQ expan- overexpression of either Hdj1 or Hdj2 suppressed aggre-
sion alone is being expressed to very high levels within gation and toxicity of polyQ-expanded ataxin-3 (Chai et
a day of transfection. The rate-limiting step would not al., 1999).
be the production of the exogenous, expanded polyQ Thus, chaperones are likely to play at least two roles
fragment, but rather the production of a clipped frag- in pathogenesis. On one hand, they seem to affect the
ment of endogenous polyQ protein. This speculative formation of NIs; this role may be a response to stress
model would also explain why each polyQ expansion (Chai et al., 1999) and is likely to be protective. On the
disease presents with a different pathology. Toxicity other hand, they may create the very situation that leads
derives not from the polyQ moiety that is common to to toxicity. For example, inappropriate association with
all eight proteins but from the rest of the protein, unique chaperones could lead to mislocalization of a polyQ-
to each one. The question of whether expression of expanded protein, as the overexpression of chaperones
the nonpolyQ protein of a disease can cause disease- such as the Hsp40 cognate Ydj1 can cause the mislocal-
related toxicity remains to be addressed. ization of proteins in yeast (Blumberg and Silver, 1991).
From the above discussion, it seems likely that polyQ Alternatively, chaperones could stabilize the toxic con-
formation of the polyQ-expanded protein or be requiredexpansions cause toxicity from the nucleus in a manner
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both the androgen receptor (the protein mutated in an-
other polyQ expansion disease, SBMA) and htt (Dia-
mond et al., 2000).
In light of the studies discussed here, the model for
cellular pathogenesis in polyQ expansion diseases be-
comes both more complex and more simple (Figure 1).
Neither ubiquitination nor nuclear aggregate formation
appear to contribute to toxicity, simplifying the system
considerably. In contrast, the mechanism whereby a
toxic portion of the protein may cause disease remains
unknown. As previously proposed, the polyQ expansion
likely causes the mutant protein to adopt a new confor-
mation that leads to altered interactions with a range of
proteins. Some of these proteins, formerly candidates
as mediators of toxicity, may not be important to toxicity;
these include some chaperones (e.g., Hsp104, appar-
ently required for the formation of nuclear aggregates)
and the ubiquitin-dependent proteolytic machinery.
Other interacting proteins, such as transcription factors,
are present within the nucleus. This type of interaction
may be the cause of toxicity that eventually leads to cell
death, and transcription factors are prime candidates.
The very recent publication of an inducible/repressible
mouse model for HD (Yamamoto et al., 2000) gives us
Figure 1. A Model for PolyQ Expansion±Mediated Cell Toxicity great hope on two levels. First, by showing that the
cellular and behavioral symptoms caused by the expres-The disease-causing protein is shown in blue, with the mutant, polyQ
repeat in orange. As shown on the left, the expansion of the polyQ sion of a mutant polyQ fragment can be reversed when
tract would lead to the production by proteolytic clipping of a toxic expression of the polyQ protein is abrogated, the data
fragment. Ubiquitination of this fragment, which may or may not be demonstrate that both the cellular and the behavioral
the polyQ-containing moiety, may partially protect cells from toxic-
symptoms of a polyQ expansion disease are reversible.ity, by driving proteasome-mediated degradation or aggregate for-
This is great news for patients and their relatives: drugsmation. In the pathway shown on the right, the mutant protein would
will work! Secondly, this system may allow us to clearbe degraded by a cellular pathway that may overlap with a pathway
that would mediate turnover of the wild-type protein. In this scheme, up many of the discrepancies in the field by providing
however, the polyQ-containing moiety would be resistant to degra- us with the tools to ask which of the changes observed
dation and would be the cause of toxicity. Whatever the mechanism to date are reversed as pathology is reversed. For exam-
whereby the toxic fragment is produced, it needs to enter the nu- ple, if particular chaperones are required for the forma-
cleus to exert its effects, eventually leading to cell death.
tion of protective aggregates or to prevent inappropriate
protein±protein interactions, chaperone inhibition should
make cells more susceptible to transient expression of
for appropriate presentation of substrates to the pro- mutant htt. Alternatively, chaperones could be stabiliz-
teasome. ing a toxic form of htt, perhaps by preventing the degra-
With regard to the effects of polyQ expansion proteins dation of the toxic form. In this case, chaperone inhibi-
on transcription, it has recently been reported that large tion could actually protect against transient expression
changes in transcription occur very soon after the ex- of mutant htt in the Yamamoto mouse. Similarly, in the
pression of mutant ataxin-1 protein in transgenic mice case of transcription factors, it will be possible to distin-
(Lin et al., 2000) or of mutant htt in rat cells (Li et al., guish between those proteins whose changes in ex-
1999). Lin et al. identify seven different genes whose pression correlate with induction and repression of the
transcription is altered in mice transgenic for mutant polyQ-htt fragment and those that do not. The latter
ataxin-1. Six of these genes (type 1 IP3 receptor, type 2 class will comprise proteins that are a consequence of
sarcoplasmic endoplasmic reticulum calcium ATPase cellular pathology, but the former may be important in
[SERCA 2], prenylcysteine carboxylmethyltransferase initiating or driving that pathology. This separation of
[PCCMT] type 1, inositol polyphosphate 5-phosphatase, cause and consequence at the cellular level will allow
transient receptor potential [TRP] type 3, and excitatory us to distinguish which of the cellular changes are ap-
amino acid transporter type 4) are downregulated. In propriate targets for drug design.
contrast, a1-antichymotrypsin is upregulated. It is pos-
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Note Added in Proof
While this minireview was in press, Luthi-Carter et al. reported the
results of a microarray analysis of gene expression in two mouse
models of HD. When comparing the levels of expression of almost
6000 genes between transgenic mice expressing mutant exon1 with
an expanded polyQ tract and wild-type littermates, z80 genes
showed decreased levels of expression while 22 were expressed
at higher levels in 6-week-old mice. Many of the genes fall into two
broad categories: neural transmitter/signaling and calcium homeo-
stasis, and disruption of either of these processes could lead to
cellular toxicity. These changes may reflect a direct interaction be-
tween a toxic fragment of htt and a transcription factor(s), or they
may represent an indirect reaction to polyQ-mediated toxicity. For
more information, see: Luthi-Carter, R., Andrew, A., Peters, N.L.,
Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor,
B.S., Penney, E.B., Schilling, G., et al. (2000). Decreased expression
of striatal signaling genes in a mouse model of Huntington's disease.
Hum. Mol. Genet. 9, in press.
